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Blood	viscosity	composed	of	vascular	and	rheologic	
components	is	considered	as	important	parameter	in	a	
wide	variety	of	clinical	disorders,	including	cancer.	The	
normal	range	for	blood	viscosity	is	3.2	±	0.4	miliPascal	
(mPas)	[1].	Elevated	plasma	viscosity	was	reported	in	
patients	with	breast	and	ovarian	cancer	[2–5].	Increased	
plasma	viscosity	 impairs	blood	 flow	properties	and	
may	induce	hypoxia	in	the	microcirculation	that	favors	
thrombosis,	settlement	of	tumor	cells	and	thus	metas-
tasis.	The	viscosity	of	the	blood	is	primarily	related	to	
hematocrit	but	also	to	the	amount	of	albumin,	fibrinogen	
and	other	macromolecules	present	in	the	blood	[6].	
Non-Hodgkin’s	lymphoma	(NHL)	is	a	malignant	dis-
order	which	curability	is	highly	possible	[7].	Important	
prognostic	factors	of	NHL	are	the	stage	of	the	disease	
and	international	prognostic	index	(IPI)	value	as	well	as	
hemoglobin	level	[8,	9].	Hemoglobin	levels	<	11	g/dL	
were	shown	to	be	a	poor	prognostic	criteria	for	survival	
of	NHL	patients	[9].	The	aim	of	our	study	was	to	analyze	
the	changes	in	blood	viscosity	in	newly	diagnosed	NHL	
patients	on	the	background	of	alterations	in	fibrinogen,	
albumin	and	hemoglobin	levels.
Twenty	newly	diagnosed	patients	with	histologically	
documented	diffuse	large	B	cell	NHL	were	enrolled	in	
the	study.	Written	 inform	concent	was	 taken	 from	all	
patients.	Patients	possessing	diabetes	mellitus,	chronic	
renal	failure,	hypertension,	coronary	vascular	disease,	
infectious	disease,	collagen	vascular	disease	or	co-
agulopathy	were	excluded	from	the	study.	The	median	
age	of	the	patients	was	52	years	(range:	26–79),	the	
male/female	ratio	was	14/6.	Patient’s	characteristics	
are	presented	in	the	Table	(stage	I,	n	=	7;	stage	II,	n	=	4;	
stage	III,	n	=	7,	stage	IV,	n	=	2;	by	IPI	score,	IPI	0,	n	=	1;	
IPI	1,	n	=	3;	IPI	2,	n	=	6;	IPI	3,	n	=	6;	IPI	4,	n	=	4).	
Table. Patient’s characteristics and blood viscosity 
No of 
patient Sex Age Stage LDH ENIN IPI
Hb 
(g/dL) Fbr
Blood Viscosi­
ty (miliPascal)
1 M 39 3E 445 1 3 9.3 243 4.5 ± 0.2
2 F 59 1E 167 1 0 12.9 226 7.8 ± 0.3
3 M 66 1E 186 1 2 16.6 194 7.9 ± 0.2
4 F 38 2E 736 1 2 8.8 228 4.6 ± 0.2
5 M 72 1E 156 1 2 13.3 216 7.7 ± 0.2
6 M 29 3E 296 1 3 11.1 243 4.8 ± 0.1
7 M 77 4 318 0 4 11.6 256 5.7 ± 0.1
8 M 52 2E 259 2 4 11.8 251 4.7 ± 0.2
9 F 30 2E 235 1 2 12.3 223 7.2 ± 0.3
10 F 65 3E 373 1 3 9.7 236 3.7 ± 0.1
11 M 64 1 129 0 2 7.9 241 5.3 ± 0.2
12 M 41 3 328 0 3 12.8 264 4.7 ± 0.2
13 M 26 4 510 0 4 15.1 236 5.8 ± 0.2
14 M 42 1 123 0 1 8.8 214 7.6 ± 0.2
15 M 79 1E 141 1 3 11.2 181 4.7 ± 0.2
16 M 65 3 263 0 4 10.8 177 4.0 ± 0.1
17 M 29 3s 164 0 1 12.1 215 5.7 ± 0.2
18 M 53 1E 136 1 1 13.4 251 8.2 ± 0.3
19 F 63 2E 233 1 3 10.8 190 4.4 ± 0.2
20 F 51 3 290 0 2 12.6 244 5.9 ± 0.1
Notes: ENIN — extranodal involvement number; M — male; F — female; 
Hb — hemoglobin; LDH — lactate dehydragenase (normal:100–200 U/L), 
Fbr — fibrinogen (normal:170–400 mg/dL).
Blood	samples	in	a	volume	of	5	cc	were	taken	prior	
to	chemotherapy	using	tubes	with	anticoagulant	and	
immediately	frozen	at	–40	°C.	On	the	day	of	measure-
ment,	all	samples	were	melted	and	their	viscosity	was	
measured	at	37	°C	in	a	Brookfield	DV-II	+	(USA)	machine	
which	was	calibrated	with	distilled	water.	Each	sample	
was	measured	four	times	and	the	average	of	the	mea-
surements	was	taken	(mean	±	levels,	see	the	Table).
Staging	procedures	in	all	patients	were	done	using	
complete	blood	count,	blood	chemistry,	lactatdehydro-
genase	 (LDH)	 level	and	erythrocyte	sedimentation	
rate,	computed	 tomography	and	bone	marrow	bio-
psy.	 IPI	 scores	were	calculated	according	 to	stage	
and	clinical	signs.	The	parameters	which	may	have	
an	effect	on	viscosity	such	as	 fibrinogen	 (Beckman	
Coulter	ACL®	10000)	and	albumin	(Beckman	Coulter	
Synchron	LX®	20	Autoanalyser)	were	measured	 in	
blood	analyses	before	treatment.	
To	assess	the	trends,	we	used	the	median	values	of	
intake	in	each	category.	95%	confidence	intervals	for	
all	relative	risks	were	calculated.	P	values	<	0.05	were	
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considered	significant.	For	 independent	prognostic	
parameters,	Spearman’s	Rho	correlation	was	used.	
Median	blood	 viscosity	was	 found	 to	be	5.5	±	
1.46	miliPascal	(range:	3.7–8.2,	normal:	3.2	±	0.4)	[1].	
Blood	viscosity	inversely	correlated	with	LDH,	IPI	score,	
and	stage	(p	=	0.02,	r	=	–0.51;	p	=	0.03,	r	=	–0.63;	and	
p	=	0.04,	r	=	–0.45,	respectively)	and	positively	correlat-
ed	with	hemoglobin	level	(p	=	0.02,	r	=	0.65)	(Fig.	1,	2).	
Sex,	age,	fibrinogen	level,	and	extranodal	involvement	
were	not	associated	with	blood	viscosity	(p	=	0.57,	p =	
0.95,	p	=	0.57	and	p	=	0.84	respectively).	Albumin	levels	
were	shown	to	have	a	significant	inverse	correlation	with	
the	stage	(p	=	0.02,	r	=	–0.516)	and	positive	correlation	
with	blood	viscosity	(p =	0.05,	r	=	0.442).
fig. 1. Correlation	of	mean	blood	viscosity	with	IPI	score
fig. 2. Correlation	of	mean	blood	viscosity	with	 the	stage	of	
the	disease
This	is	the	first	report	on	the	blood	viscosity	in	NHL	
patients	showing	its	inverse	correlation	with	the	stage	
of	the	disease	and	IPI	score.	Elevated	levels	of	acute	
phase	substances	such	as	fibrinogen,	C-reactive	pro-
tein	in	NHL	patients	may	contribute	to	these	results.	
In	conclusion,	we	believe	 that	evaluation	of	blood	
viscosity	may	be	used	as	an	easy	and	useful	marker	of	the	
disease	progression.	Further	trials	may	demonstrate	the	
impact	of	blood	viscosity	on	prognosis	in	NHL	patients.
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вязкость крови у больных диффузной в-клеточной 
неходжкинской лимфомой 
Цель: анализ вязкости крови в качестве маркера возможного маркера прогрессии заболевания у больных неходжкинской 
лимфомой (НХЛ). Методы: вязкость крови 20 пациентов НХЛ (стадия I, n = 7; стадия II, n = 4; стадия III, n = 7; стадия IV,                
n = 4) измеряли на приборе Brookfield DV-II + (���).          Результаты: вязкость крови больных НХЛ (средняя величина: 
5.5 ± 1.46 миллиПаскаль) находилась в обратной корреляции с уровнем лактатдегидрогеназы (ЛДГ), величиной между-
народного прогностического индекса (IPI) и стадией заболевания (    p = 0,02, r = –0,51;   p = 0,03, r = –0,63;   p = 0,04, r =  
–0,45 соответственно) и в прямой зависимости от уровня гемоглобина (p = 0,02, r = 0,65)).   Выводы: согласно полученным 
данным, вязкость крови можно рассматривать в качестве маркера течения заболевания у больных НХЛ наряду с уровнем 
ЛДГ и показателем скорости оседания эритроцитов.
Ключевые слова: вязкость крови, неходжкинская лимфома.
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